I. History
Historically, adrenergic receptors were divided into two major types, α-and β-adrenergic receptors (1) . Theadrenotropic receptors are those hypothetical structures or systems located in, on or near the muscle or gland cells affected by epinephrine (2) . The concept of a receptive mechanism was introduced by Langley (3, 4) to explain the action of curare on skeletal muscle. Dale was probably the first to make significant use of the receptor concept in connection with the sympathetic nervous system. In his classical paper (5) on the sympatholytic action of the ergot alkaloids, he recognized that what he called the sympathetic myoneural junction could also be called 'the receptive mechanism for adrenaline'; and he used this mechanism to ex plain the fact that the ergot alkaloids prevented only the motor (excitatory) actions of epinephrine and had no effect on the inhibitory actions of epinephrine or on the excitatory actions of barium or pituitrin.
Subtypes of Alpha Adrenergic Receptors(11)
The initial evidence for subtypes of α 1-adrenergic receptors was obtained in studies of adrenergic receptor mediated contraction of various vascular smooth muscles (6, 7). Data from radioligand binding studies, on the other hand, have produced a consistent definition of α adrenergic receptor subtypes, which has been confirmed by the molecular cloning of these receptors (8) . α-adrenergic receptor 
II. Conclusion
A major message of this review is that α 1, α 2,are the two major subtypes of α-adrenergic receptors, and that α 1-and α 2-adrenergic receptors are not more closely related to each other. The identification of multiple receptor subtypes for the major types of adrenergic receptors has obvious implications for drug therapy. It is to be expected that more and better selective drugs for the various subtypes will be developed in the near future. These will be important research tools as well as potentially new therapeutic agents. A major impediment at the current time to the development of better therapeutic agents is a paucity of knowledge as to which functions are mediated by which receptor subtypes. This is an area that clearly needs immediate attention. Current studies under way on the localization of the various subtypes in various tissues and regions of tissues may help to correlate receptor subtype with function. It appears that receptor subtype-specific antibodies may be developed in the near future and these will also be an important tool. Another important area in the next few years will be a study of subtype-specific regulation of the protein and mRNA level. Further in the future it seems reasonable to expect that it may be possible to regulate levels of receptors and G proteins in order to produce therapeutic effects, rather than regulating the degree of receptor occupancy by the agonist as is currently done.
